Cedric Francois Sells 6,007 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 6,007 shares of the business’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $29.96, for a total transaction of $179,969.72. Following the completion of the transaction, the chief executive officer now directly owns 301,408 shares of the company’s stock, valued at $9,030,183.68. The trade was a 1.95 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Cedric Francois also recently made the following trade(s):

• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total transaction of $179,288.90.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS opened at $30.39 on Thursday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $71.90. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of -14.97 and a beta of 0.94. The business has a 50-day moving average of $31.95 and a 200-day moving average of $33.25.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The company had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s revenue was up 78.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.17) EPS. On average, equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. State of New Jersey Common Pension Fund D grew its stake in shares of Apellis Pharmaceuticals by 6.6% during the second quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock valued at $1,735,000 after acquiring an additional 2,820 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in Apellis Pharmaceuticals by 42.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after purchasing an additional 39,931 shares in the last quarter. Amalgamated Bank increased its holdings in Apellis Pharmaceuticals by 5.4% during the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after purchasing an additional 359 shares during the last quarter. Profund Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 90.7% in the 2nd quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock valued at $1,648,000 after purchasing an additional 20,435 shares in the last quarter. Finally, HighVista Strategies LLC boosted its stake in shares of Apellis Pharmaceuticals by 4.1% during the 2nd quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock valued at $290,000 after buying an additional 300 shares during the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on APLS shares. William Blair began coverage on Apellis Pharmaceuticals in a report on Wednesday, October 16th. They issued an “outperform” rating for the company. Oppenheimer dropped their target price on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Scotiabank decreased their price target on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 6th. Morgan Stanley started coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price objective for the company. Finally, Evercore ISI raised shares of Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).